Pharmaceutical - Anti-virals, China

Filter

Current filters:

Anti-viralsChina

Popular Filters

Presidio out-licenses HCV NS5A inhibitor PPI-668 to Pharco and Ascletis

Presidio out-licenses HCV NS5A inhibitor PPI-668 to Pharco and Ascletis

11-11-2014

Privately-held USA-based Presidio Pharmaceuticals has out-licensed its hepatitis C virus NS5A inhibitor…

Anti-viralsAscletis PharmaceuticalsChinaLicensingPharco PharmaceuticalsPharmaceuticalPPI-668Presidio PharmaceuticalsRest of the World

Global Fund taps pharmaceutical expertise in China

02-04-2014

The Global Fund is deepening its partnership with China by tapping the expertise of Chinese pharmaceutical…

Anti-viralsAntibiotics and Infectious diseasesChinaGlobalMarkets & MarketingPharmaceuticalProductionRegulation

Leading Chinese hepatitis B vaccine makers stop production; Pfizer drug import halted

03-01-2014

China’s Food and Drug Administration announced on January 2 that the country’s three leading manufacturers…

Anti-viralsAntibiotics and Infectious diseasesAsia-PacificBioKangtaiChinaFluconazolePfizerPharmaceuticalRegulationVaccines

China bans BioKangtai hepatitis B vaccine

26-12-2013

Chinese authorities on Friday issued a circular to ban the use of the recombinant hepatitis B vaccine…

Anti-viralsAsia-PacificBioKangtaiChinaHealthcarePharmaceuticalRegulationVaccines

COMPANY SPOTLIGHT

Menarini

Back to top